Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34662895/
With the advances in mantle cell lymphoma (MCL) frontline treatment over the last two decades, we sought to characterize the frontline treatment pattern change and its association with outcomes. Patients...
An Aggressive Presentation of Mantle Cell Lymphoma With Unique Molecular Features - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34646650/
Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma (NHL) with a dismal prognosis. The pathogenesis of MCL is complex and involves molecular alterations in various genes and pathways including...
Mantle Cell Lymphoma Involving Tonsils: A Clinicopathologic Study of 83 Cases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34655612/
We report 83 cases of mantle cell lymphoma (MCL) involving the tonsil as initial manifestation (IM). The median age at the time of tonsillar involvement was 58 years (range, 35...
Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34654437/
Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by uncontrolled proliferation of B-cells and severe immune dysfunction. Chemo(immuno)therapies (CIT) have traditionally aimed to reduce tumor burden without fully understanding...
-
Leukemia and Lymphoma Connect4yrKey Points • Source: Journal of Experimental & Clinical Cancer Research (BMC) • Conclusion/Relevance: “There is still need for more research to understand the effects of each treatment option (monotherapies and combinations) in the Show More
Zanubrutinib Monotherapy for Relapsed or Refractory Non-Germinal Center Diffuse Large B-Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34638136/
The non-germinal center (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton's tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity...